Abstract Kirsten rat sarcoma (KRAS) mutations are key drivers of oncogenesis and therapy resistance in colorectal cancer (CRC), yet the underlying molecular mechanisms and effective targeted therapies are currently limited. Here we identify thyroid hormone receptor interactor 6 (TRIP6) phosphorylation as a critical mechanism of immune evasion in KRAS-mutant (KRAS/MT) CRC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Guideng
Contact Guideng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack